Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifeprunox Safety Extension in Schizophrenia
NCT00861497Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Jan 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bifeprunox in schizophrenia, sponsored by Lundbeck. Started Jan 2006; status: terminated.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00861497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861497.